All In Biotech

Drug Trial Radar · NCT03752138

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Phase I Study of TK216 in Patients With Relapsed and Refractory Leukemias

Last checked: Nov 19, 2026Latest source record: May 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 31, 2019

Primary completion

Dec 31, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Nov 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects and best dose of TK216 and decitabine when given together in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as TK216 and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia

Interventions

  • Group 1: TK216Drug

    Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.

  • Group 2: TK216Drug

    Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.

  • Part 2: Decitabine 10mg/m2Drug

    10mg/m2 by vein on Days 1-10 of a 28 day cycle.

  • Part 2: Decitabine 20 mg/m2Drug

    20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.

  • Expansion Phase TK216Drug

    Expansion cohort will receive the RP2D of TK216

  • Expansion Phase DecitabineDrug

    Expansion cohort will receive the RP2D of Decitabine

  • Part 2: TK216Drug

    Recommended dose from Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to 30 days
  2. Response rateTime frame: Up to 30 days
  3. Overall survivalTime frame: Up to 1 year
  4. Disease free survivalTime frame: Up to 1 year
  5. Duration of disease controlTime frame: Up to 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.